Larimar Therapeutics (LRMR) Free Cash Flow: 2013-2020
Historic Free Cash Flow for Larimar Therapeutics (LRMR) over the last 7 years, with Dec 2020 value amounting to -$10.3 million.
- Larimar Therapeutics' Free Cash Flow fell 28.80% to -$10.3 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$42.7 million, marking a year-over-year decrease of 87.25%. This contributed to the annual value of -$71.3 million for FY2024, which is 111.84% down from last year.
- Per Larimar Therapeutics' latest filing, its Free Cash Flow stood at -$10.3 million for Q4 2020, which was up 8.67% from -$11.2 million recorded in Q3 2020.
- Larimar Therapeutics' Free Cash Flow's 5-year high stood at $3.5 million during Q2 2019, with a 5-year trough of -$18.2 million in Q1 2016.
- For the 3-year period, Larimar Therapeutics' Free Cash Flow averaged around -$9.8 million, with its median value being -$11.5 million (2018).
- As far as peak fluctuations go, Larimar Therapeutics' Free Cash Flow surged by 126.12% in 2019, and later slumped by 450.14% in 2020.
- Larimar Therapeutics' Free Cash Flow (Quarterly) stood at -$8.7 million in 2016, then decreased by 13.81% to -$9.9 million in 2017, then fell by 20.11% to -$11.8 million in 2018, then skyrocketed by 32.80% to -$8.0 million in 2019, then decreased by 28.80% to -$10.3 million in 2020.
- Its Free Cash Flow stands at -$10.3 million for Q4 2020, versus -$11.2 million for Q3 2020 and -$12.2 million for Q2 2020.